A study on changes of coagulation inhibitors and fibrinolysis inhibitors in patients with liver cirrhosis and hepatoma

J Korean Med Sci. 1991 Mar;6(1):1-6. doi: 10.3346/jkms.1991.6.1.1.

Abstract

The authors conducted an investigation focusing mainly on the activities of the inhibitory factors of the coagulation and fibrinolysis processes in 35 normal adults and 72 liver cirrhosis and/or hepatoma patients. The activities of antithrombin III, protein C, and alpha 2-plasmin inhibitor were reduced to less than 50% in patients with decreased hepatic synthetic function while lupus anticoagulant was detected in more than 50% of patients with decreased hepatic synthetic function. Hemostatic abnormalities in advanced lived diseases may be caused partly by a decrease of coagulation and fibrinolysis inhibitors and the presence of lupus anticoagulant.

MeSH terms

  • Adult
  • Antifibrinolytic Agents / blood
  • Blood Coagulation Factors / antagonists & inhibitors
  • Blood Coagulation Factors / immunology
  • Blood Coagulation Factors / metabolism
  • Carcinoma, Hepatocellular / blood*
  • Hemostasis
  • Humans
  • Liver Cirrhosis / blood*
  • Liver Neoplasms / blood*
  • Lupus Coagulation Inhibitor

Substances

  • Antifibrinolytic Agents
  • Blood Coagulation Factors
  • Lupus Coagulation Inhibitor